683 Capital Management’s Soleno Therapeutics, Inc. Series A Warrant SLNOW Stock Holding History

683 Capital Management’s Portfolio SLNOW Stock Details SLNOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-602,443	Closed	-$186K	–	209
2018 Q4	$186K	Buy	+602,443	New	+$64.8K	0.01%	138
2018 Q2	–	Sell	-602,443	Closed	-$273K	–	175
2018 Q1	$273K	Buy	+602,443	New	+$100K	0.02%	113

Other funds holding SLNOW

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

683 Capital Management's SLNOW Position: Q1 2019 in Review

683 Capital Management sold out of Soleno Therapeutics, Inc. Series A Warrant (SLNOW) in Q1 2019, closing a stake of 602,443 shares — an estimated $186K sold.

683 Capital Management first reported a position in SLNOW in Q1 2018 and held it in 2 quarters. The position peaked at $273K in Q1 2018. 2 funds tracked by Wall St. Rank hold SLNOW as of Q1 2019.

683 Capital Management reported no remaining Soleno Therapeutics, Inc. Series A Warrant position as of Q1 2019 after selling out during the quarter.
683 Capital Management sold 602,443 Soleno Therapeutics, Inc. Series A Warrant shares in Q1 2019, an estimated $186K.
683 Capital Management first reported a position in Soleno Therapeutics, Inc. Series A Warrant in Q1 2018 and held it in 2 quarters.
683 Capital Management's Soleno Therapeutics, Inc. Series A Warrant position peaked at $273K in Q1 2018.
2 funds tracked by Wall St. Rank held Soleno Therapeutics, Inc. Series A Warrant as of Q1 2019.

Based on 683 Capital Management's 13F filing for Q1 2019, filed 15 May 2019.